Tumor necrosis factor (TNF)-treated 3T3-L1 adipocytes were used as a model for studying the effects of systemic inflammation on adipose tissue. Lipopolysaccharide-treated monocyteconditioned medium or recombinant human TNFa induced morphological dedifferentiation of the adipocytes and led to loss of adipocyte specific gene expression. Gel shift, Southwestern and Western immunoblot analysis demonstrated that dedifferentiation was preceded by a decrease in the DNA binding activity and protein level of the transcription factor CCAAT/enhancer binding protein (C/EBP). Liver activating protein, a related protein that binds identical DNA sequences, increased during cytokine treatment. Both proteins activate specific enhancer elements located in the promoter region of many genes whose transcription is altered during systemic inflammation. Pulsechase labeling followed by immunoprecipitation demonstrated that C/EBP is a rapidly turning over protein in adipocytes and that cytokine treatment led to a specific, time dependent decrease in its rate of synthesis. Because C/EBP binding sites have been shown to play an important role in regulating the expression of genes involved in adipocyte metabolism, we propose that the TNF-induced changes in the complement of transcription factors binding those sites may be important in the pathogenesis of inflammation-induced atrophy of adipose tissue. (J. Clin. Invest. 1992. 89:223-233.)
Introduction
Weight loss associated with atrophy of adipose tissue is commonly encountered in human disease. This occurrence and the associated weakness and lassitude, referred to as the syndrome of cachexia, often contributes directly to the morbidity associated with chronic illness. The syndrome develops to varying degrees in many patients in advanced stages of illness (1) . Tu-mor necrosis factor (TNF),' a 17-kD cytokine secreted from activated macrophages, has been postulated to play a role in the pathogenesis of cachexia. Originally identified as cachectin, TNF has been shown to be a mediator of profound inanition accompanying chronic protozoal infection in rabbits (2) . Subsequent correlative clinical studies have demonstrated elevated levels of TNF in the serum of patients with chronic bacterial infections (3), parasitic infections (4), cancer (5) , AIDS (6) , and severe chronic heart failure (7) . Sustained elevation of serum TNF levels in experimental animals leads to profound weight loss associated with atrophy ofall visible body fat, giving rise to a syndrome similar to human cachexia (8) .
TNF causes a dramatic morphological dedifferentiation of adipocytes in culture (9) . Treatment of adipocytes with TNF is associated with a decrease in the activities and rates ofsynthesis of key adipogenic enzymes (10, 1 1) . This later event is, in turn, associated with a repression of the transcription of a subset of adipocyte specific genes (9, 12) . It thus appears that the actions of TNF on cultured adipocytic cells can serve as a cell culture model for some ofthe important biochemical events associated with the development of human cachexia.
CCAAT/enhancer binding protein (C/EBP) is a transcription factor enriched in liver and adipose tissue, that binds and activates cis-acting regulatory elements in the promoter regions ofmany genes that are expressed at high levels in adipose tissue (13) (14) (15) (16) . A feature common to many of the genes activated by C/EBP is an apparent role for the gene products in the regulation of intermediary metabolism in adipose tissue and liver (17) . Angiotensinogen mRNA is also induced during the differentiation of 3T3-Ll fibroblasts into adipocytes (18) and this induction coincides with the accumulation of C/EBP DNAbinding activity in the cell nuclei (McGehee, R. E., Jr., et al., unpublished observations). The link between C/EBP and expression ofthe adipocytic phenotype is further strengthened by the fact that C/EBP is induced to high levels during the terminal differentiation of 3T3-L I cells into adipocytes; C/EBP protein is undetectable in fibroblastic 3T3 cells ( 14, 19) . Recently, other DNA-binding proteins have been identified that are capable ofbinding the same DNA sequences that bind C/EBP. One such transcription factor, liver activating protein (LAP, 20) , appears to account for much of the C/EBP site-specific DNAbinding activity present in nuclei that is not attributable to C/EBP itself. Identical or homologous cDNA's have been identified by several other groups and the encoded proteins are referred to as NFIL-6 (21), IL-6DBP (22) , and AGP/EBP (23) . LAP and C/EBP bind promoter elements involved in cytokine-induced transcriptional regulation of the activity of several acute phase responsive genes, suggesting a role for these factors in mediating cytokine-induced changes in the expression of these genes.
Our studies on the regulation of the angiotensinogen gene in liver during the acute phase response led to the identification ofa hormonally induced enhancer unit consisting oftwo glucocorticoid responsive elements and a cytokine responsive 28-bp palindromic sequence termed the acute phase responsive element (APRE, [24] [25] [26] . The APRE binds, in a mutually exclusive manner, members of either of two classes of transcription factors: the interleukin-1 (IL-1) and TNF-inducible nuclear factor kappa B (NFKB) or a heterogeneous family of C/EBPlike proteins (27) . In the course of these studies we made the observation that induction ofthe acute phase is associated with a decrease in the level of C/EBP in rat liver nuclei (Ron, D., et al., unpublished observations).
The acute phase response, induced by lipopolysaccharide injection into rats, is associated with elevated levels ofcirculating TNF (10) . Because of the possibility that C/EBP and LAP play a role in regulating the transcriptional activities of genes involved in adipocyte metabolism, and because conditions associated with elevation of TNF are also associated with a repression of adipocyte metabolism, we sought to determine whether an in vitro model for the acute phase is associated with a change in the level of C/EBP and LAP in adipocyte nuclei.
Methods
Bacterial expression ofLAP and C/EBP and DNaseIfootprinting ofthe angiotensinogen promoter. Bacterial expression plasmids encoding the DNA-binding domains of LAP and C/EBP were constructed by amplifying, in the polymerase chain reaction (PCR), a fragment of cDNA encoding amino acid residues 211-297 (21) and residues 271-359 (28), respectively. C/EBP was amplified, using as a target, a plasmid containing the rat cDNA (gift of S. McKnight). LAP was amplified from HepG2 cell cDNA and therefore encodes the DNA-binding domain of its human homologue, NFIL-6 (the amino acid sequences of the two homologues, in the amplified region, are virtually identical). The PCR primers were constructed to incorporate a convenient Nco 1 site at the 5' end of the amplified sequence which encodes an in-frame initiator methionine and allows directional ligation ofthe cDNA into the bacterial expression vector pET 8c (29) . Sequence of the C/EBP primers: 5'GGC GGG GCC GCC ATG GGC AAG GCC AAG AAG 3' and 5' GGA TCC TCA CGC GCA GTT GCC CAT TGC CTT GAC 3'; sequence of the NFIL-6 primers: 5' GCG CCC TCC ATG GTC AAG AGC AAG GCC AAG AAG ACC GTG G 3' and 5' GCG GGG GAT CCT CGA GCA GTG GCC GGA GGA GGC GAG CAG G 3'. The recombinant proteins were expressed in the pLysS lysogenized strain of Escherichia coli BL21, DE.3. Crude bacterial suspensions were lysed by sonication, and heated to 65°C for 1O min. The heat stable recombinant proteins were recovered in the supernatant of the lysate. DNaseI footprinting was performed as described previously (30) . As little as 0.5 ,ll of the bacterial lysate, containing 50 ng of recombinant protein, produces a clear DNaseI protected region over the APRE. A full length bacterial expression vector for C/EBP was constructed by ligating the Nco l fragment of the rat C/EBP cDNA into the Ncol site of a pET8c plasmid that had an inserted oligonucleotide encoding the four carboxy-terminal amino acids of C/EBP followed by a stop codon. The LAP expression vector was a gift of Ueli Schibler and Patrick Descombes (20) .
Analysis ofnuclear proteins from cytokine-treated adipocytes. 3T3-Ll fibroblasts were induced to differentiate to adipocytes as described previously (31) . At various times before harvest (on day seven of the differentiation protocol), 0.5% vol/vol of conditioned medium prepared from LPS-treated raw 264.7 monocytic cells (2) was added to the culture medium. Nuclear extracts were prepared from the cells (32) . Electrophoretic mobility shift assays (EMSA) were performed using 7
Mg of nuclear protein (30) . The DNA probe consisted of the APRE point mutant M6, a sequence that binds the C/EBP-like proteins with an affinity indistinguishable from wild type, yet fails to bind NFKB (27) . Bound complexes and free probe were resolved on a 6% nondenaturing polyacrylamide gel. In the antibody supershift experiments 1 Ml ofantisera or control nonimmune antisera was added to the nuclear extract and incubated at room temperature for 20 min before the EMSA. For analysis ofNFKB DNA-binding in EMSA KBE probe was used (27) . For analysis ofcytokine induced changes in the activity ofa C/EBP binding site-containing promoter, pools of stably transfected 3T3-LI cells (> 30 pools per experiment) containing the reporter plasmid [M6]X4pS9rATLUC (27) were induced to differentiate and after attainment of the adipocytic phenotype were treated with 0.5% vol/vol monocyte-conditioned medium for the indicated period oftime. Cytosol obtained in the course of preparation of nuclear extracts were assayed directly for luciferase activity (30 Southwestern and Western immunoblots. 80-Ag aliquots of nuclear protein were fractionated by 1 1% SDS-PAGE and electroblotted onto a nitrocellulose filter. For Southwestern blot the filter was denatured in 6 M guanidine hydrochloride (Gd-HCl) in TNE-50 (TNE-50: 20 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothrietol), renatured by four successive twofold dilutions in TNE-50, washed free of Gd-HCl, blocked in 10% wt/vol nonfat dry milk in TNE-50 and reacted with 32P-labeled APRE M6 probe (0.5 X 106 cpm/ml at 2 X 106 cpm/pM) in TNE-50 that contained 10 Mg/ml poly dldC as a nonspecific competitor. For Western immunoblot analysis, the nitrocellulose filter was denatured in 6 M Gd-HCl, washed free ofthe salt in PBS that contained 0.2% Tween-20, blocked in the same solution containing 10% nonfat dry milk, and reacted with the specific rabbit polyclonal antiserum. C/EBP was detected with a 1:200 dilution ofthe previously described alpha-14 antipeptide antisera (gift ofS. McKnight [28] ). LAP was detected by a 1:3,000 dilution of the anti-IL-6DBP antisera raised against the bacterially expressed recombinant protein (a gift of R. Cortese and D. Ramji [22] ). CREB was detected by a 1:10,000 dilution of the R 1090 antisera directed against the sequence containing the phosphorylation box (34) . The bound primary antibody was visualized by enhanced chemoluminescent detection (ECL kit; Amersham Corp., Arlington Heights, IL) of secondarily bound horseradish peroxidaseconjugated goat anti-rabbit IgG (Bio-Rad Laboratories, Richmond, CA). For the LAP supershifts an antibody directed against a peptide corresponding to amino acids 54-70 was used. Specificity of the antisera and lack ofcross-reactivity ofthe anti-C/EBP antiserum with LAP and anti-LAP antiserum with C/EBP was documented in an antibody supershift EMSA and in Western blots using bacterially expressed C/ EBP and LAP (data not shown). Immunohistochemical staining of C/EBP was performed on the fully differentiated adipocytes exactly as described, using the anti-alpha-14 antiserum (35) .
For analyses of the effects of various cytokines on levels of nuclear C/EBP, bacterially expressed recombinant cytokines were obtained from the following sources: Human IL-6 and TNF-a from Bachem, Torrance, CA; human IL-la was a kind gift of S. Gillis, Immunex
Corp., Seattle, WA.
Immunoprecipitation of 35S-labeled C/EBP was performed essentially as described (36) . 3T3-L1 adipocytes were cultured in 60-mm plates, "5S-methionine/cysteine (Translabel; ICN Pharmaceuticals, Inc., Irvine, CA) was added (800 MCi/ml) to serum-free medium for 1.5 h followed by a variable length of cold chase. Nuclei were isolated and lysed in RIPA (Tris-buffered saline 0.5% deoxycholate, 1% Triton X-100, 0.1% lauryl sulfate) buffer. The lysate, in a volume of 500 Ml, was reacted for 1 h at 4VC with anti-C/EBP alpha 14 antiserum. The immune complexes were precipitated with Staphylococcus aureus pro-tein A bound to agarose beads. After three washes ofthe precipitates in RIPA buffer, the labeled proteins were resolved by 1 1% SDS-PAGE and visualized by autoradiography. Similar immunoprecipitation experiments were performed on whole cell extracts and gave identical results with respect to the C/EBP signal, though background bands were more abundant.
For analyses of mRNAs, 20-,ug aliquots of total cellular RNA from adipocytes were resolved on 1.2% agarose gels, transferred to nylon membranes, and analyzed by hybridization in a solution containing 50% formamide at 420C, to random prime labeled fragments ofcDNA. The 1. 1-kb Nco I fragment of C/EBP and the 0. 15-kb Pst-EcoRI fragment ofNFIL-6 cDNA containing vector p610 (the human homologue of LAP, a gift of S. Akira [21] ) were used as probes for detection of C/EBP and LAP, respectively. Actin and angiotensinogen mRNAs were detected as previously described (24) . For detection of adipsin mRNA, the adipsin cDNA probe was amplified by the polymerase chain reaction from an adipocyte cDNA library. The amplified adipsin cDNA was body labeled and used as a probe.
Nuclear run-on analysis of control and 4-h conditioned-mediatreated adipocytes were performed exactly as described (37 (due to the secretion of matrix proteins from the differentiated cells) lost its viscosity, presumably due to the secretion ofcytokine induced metallo-proteases. These morphological changes were associated with a decrease in the levels ofcytosolic mRNA encoding the representative adipocyte-specific genes: adipsin (38) and angiotensinogen (18) . Actin mRNA levels in the same sample were unaffected by cytokine treatment (Fig. 1 b) . Similar (27) . The ability of recombinant C/EBP and LAP, another dominant member of the C/ EBP-like family (20) , to bind the angiotensinogen promoter is demonstrated in Fig. 2 proteins bind the APRE with similar affinities (data not shown). An oligonucleotide corresponding in sequence to the region covered by the C/EBP footprint (the APRE) was used as a probe in an electrophoretic mobility shift assay to detect C/ EBP-like proteins in adipocyte nuclei. Treatment of the cultured adipocytes with 0.5% monocyte-conditioned medium led to a rapid alteration in the pattern of C/EBP-like DNAbinding proteins. The lower mobility complexes were reduced by such treatment and the faster mobility ones were induced (Fig. 2 b) . The C/EBP-like nature of the binding proteins detected by EMSA is suggested by their heat stability (all extracts were heated to 650C for 5 min), by the ability of anti-C/EBP and anti-LAP antisera to supershift a significant portion ofthe binding complex (Fig. 2 c) , and by sequence specific competition with unrelated oligonucleotides (data not shown). The rapidity of the response to cytokines is demonstrated by a comparison of the changes that occur in the C/EBP-like proteins with those that occur in the posttranscriptionally modified NFKB in the same nuclear extracts (Fig. 2 b, lower panel) . The antisera supershift experiments directly demonstrate the participation of C/EBP and LAP in the APRE-binding complex. Before cytokine treatment the majority of the DNAbinding activity is reactive with the anti-C/EBP serum, whereas after cytokine treatment the anti-LAP serum supershifts the majority ofthe probe (Fig. 2 c) . From these studies we conclude that treatment of adipocytes with monocyte-conditioned medium, leads to a reduction in C/EBP DNA-binding activity and an increase in LAP DNA-binding activity.
To evaluate the functional consequences of the cytokineinduced changes in C/EBP-like proteins, in terms of the activity of a promoter that binds these proteins, we made use of pools of 3T3-Ll cells stably transfected with a luciferase reporter gene drive by four copies of the angiotensinogen gene C/EBP-binding site, the M6 oligonucleotide (27) . After differentiation into adipocytes, the cells were treated with 0.5% monocyte-conditioned medium and luciferase activity was measured in the cytosol. Cytokine treatment led to a rapid and transient increase in reporter gene activity, with a maximal fivefold increase measured within four hours (Fig. 2 d) . This induction is specific to the C/EBP-binding site containing promoter because no increase in reporter gene activity was seen when control adipocytes transfected with an identically constructed cyclic AMP responsive element (CRE)-containing promoter were used (data not shown).
Cytokine-induced dedifferentiation ofadipocytes leads to a reversal of the differentiation-induced profile of C/EBP and LAP. 3T3-LI cells were induced to differentiate to adipocytes. After differentiation the cells were treated with 0.5% monocyte-conditioned medium. Nuclear extracts were prepared at several points in the course of the differentiation process and after cytokine treatment of the differentiated cells. The proteins in the extract were resolved by PAGE-SDS, blotted onto a nitrocellulose filter, and the blot was reacted with labeled Tumor Necrosis Factor and CCAA T/Enhancer Binding Protein (Fig. 3 , bottom two panels) shows that C/EBP and LAP immunoreactivity behave discordantly during differentiation and cytokine treatment, paralleling the DNA-binding activity of the respective proteins. We ascribe the apparent discrepancy between the dominant contribution of C/EBP to the DNA-binding complex of untreated adipocytes (as determined by the antiserum supershifting experiments, Fig. 2 c, lane 2) and the relatively weak 42-kD signal on the Southwestern (Fig. 3, lane  5) to the fact that C/EBP forms homodimers relatively poorly (unpublished observations). DNA binding in Southwestern depends on homodimerization and is therefore weak, whereas in the antibody supershifting experiments heteromeric configurations of C/EBP will also be detected and they are abundant in untreated cells (Fig. 2 c) . The results of the Western blot allow us to conclude that the reduction in C/EBP DNA-binding activity and increase in LAP DNA-binding activity that occur after cytokine treatment ofadipocytes, noted in both the EMSA and Southwestern blot, is due to a specific reduction in quantity of nuclear C/EBP protein and an increase in LAP protein.
To determine which of the cytokines present in the monocyte-conditioned medium accounts for the decrease in C/EBP immunoreactivity, day seven adipocytes were treated with pure preparations of recombinant cytokines expressed in E. coli. Western immunoblots of nuclear extracts of the treated cells were reacted with anti-C/EBP antisera. 24 hours of treatment with human TNF-a (50 ng/ml) or the monocyte-conditioned medium (0.5% vol/vol) led to a specific decrease in the C/EBP immunoreactivity. Human interleukin-l a (100 U/ml) had a similar but less pronounced effect. Human interleukin-6 (200 U/ml) and the peptide glucagon (1 nM) did not lead to a decrease in C/EBP immunoreactivity (Fig. 4) . The structurally related transcription factor CREB (cAMP response element binding protein) served as an invariant positive control in these assays. We conclude that TNF is the cytokine predominantly responsible for the decrease in C/EBP levels in adipocyte nuclei induced by the conditioned medium.
To follow the intracellular fate of C/EBP during cytokine treatment of the adipocytic cells we performed immunocytochemical analysis of C/EBP immunoreactivity. Fully differentiated adipocytes contain abundant C/EBP which is localized exclusively to the nucleus (Fig. 5) . This is consistent with the observations that in liver parenchymal cells C/EBP is a nuclear protein (13) . Treatment with monocyte-conditioned medium led to a time dependent decrease in nuclear C/EBP immunoreactivity. This reduction was not associated with the accumulation of the immunoreactivity in any other cellular compartment, suggesting that once C/EBP leaves the nucleus it is rapidly degraded. 24 hours of treatment with 50 ng/ml recombinant human TNFa also caused a reduction in C/EBP nuclear immunoreactivity. C/EBP turns over rapidly in adipocytes and cytokines decrease its rate ofsynthesis. To investigate the mechanism underlying the cytokine-induced decrease in C/EBP immunoreactivity we evaluated the metabolic half-life ofthe protein and its rate of synthesis under normal conditions and following cytokine treatment of the cells. Pulse-chase labeling of adipocytes followed by specific immunoprecipitation of C/EBP demonstrates that C/EBP is a labile cellular constituent with a half-life ofless than two hours (Fig. 6, lanes 4-6) . The metabolic fate of preformed C/EBP is not significantly affected by cytokine treatment ofthe cells during the chase period (Fig. 6, lanes 4, 7,  and 8 ). On the other hand treatment of the adipocytes with cytokines, before metabolic labeling led to a significant, time dependent decrease in C/EBP synthesis (Fig. 6, lanes 9-12) .
The specificity of the decrease in the synthesis rate of C/EBP is attested to by the lack of any measurable effect of cytokine treatment on the synthesis of CREB (precipitated from the C/ EBP immunoprecipitate supernatants with a specific antiserum to CREB) or the intensity of the prominent "nonspecific" bands that are coprecipitated by the C/EBP antiserum. The short half-life of C/EBP noted in the adipocytes is in marked contrast to the relatively long half-life of C/EBP when expressed in Cosl cells. It is likely that lability ofthe preformed protein is a prerequisite for the cytokine-induced fall in C/EBP levels because such a cytokine-induced fall in C/EBP was not seen in the transfected Cos 1 cells (data not shown).
Cytokine-induced decrease in C/EBP synthesis is due to a decrease in mRNA levels that occurs without a decrease in C/ EBP gene transcription. Cytokine treatment of adipocytes is associated with a progressive decrease in C/EBP mRNA levels as determined by Northern blot analysis (Fig. 7 A) . The decrease appears to account for some ofthe time dependent fall in synthesis rate of the protein, with decreased mRNA levels occurring within three hours ofcytokine treatment. Interestingly, the fall in C/EBP mRNA levels does not appear to be due to a decrease in transcription of the C/EBP gene, because nuclear run-on analysis demonstrates sustained levels of transcription four hours after cytokine treatment (by which time C/EBP mRNA levels had decreased by almost twofold, Fig. 7 B) . It would thus appear that in adipocytes inflammatory cytokines cause an early decrease in C/EBP levels in part through an mRNA destabilizing effect.
Discussion
In this study we provide evidence for the association of a cell culture model ofthe inflammatory state (refered to as the acute phase) with a reciprocal change in the ambient nuclear levels of two transcriptional regulatory proteins, C/EBP and LAP. These two DNA-binding proteins have been shown to bind indistinguishably to a variety of regulatory sequences important in modulating the expression of genes during the acute phase ( Fig. 1 and 21-23) . We demonstrate here that in cultured adipocytes treated with cytokines, C/EBP and LAP levels reciprocally decrease and increase, respectively.
The decrease in C/EBP DNA-binding activity and immunoreactivity is a specific response to the action of the inflammatory cytokines TNF, and, to a lesser degree, IL-1. This appears to be an early event in cytokine action; a decrease in the rate of C/EBP synthesis is detected within one hour of the addition of monocyte conditioned medium to cultured adipocytes (Fig. 6 , lane 10). This rapid response is consistent with the possibility that the cytokine-induced change in C/EBP levels may play a role in mediating some ofthe effects of cytokines on gene transcription, rather than being a late consequence of a cytokineinduced change in the cellular phenotype, a process that takes place over several days. The physiological mechanism that underlies the cytokineinduced decrease in C/EBP levels is a specific reduction in the synthesis rate of the protein. Based on the observation that C/EBP (in the adipocyte cell culture model) has a very short half-life, the decrease in the synthesis of C/EBP indeed would be expected to result in a rapid fall in ambient protein levels. This chain of events is consistent with a role for C/EBP in transducing some of the effects of TNF and IL-1 to alterations in gene transcription.
The decreased synthesis of C/EBP during cytokine treatment correlates with a decrease in mRNA levels, which in turn does not appear to be associated with a decreased rate ofC/EBP gene transcription. This result suggests that cytokine-induced destabilization of the mRNA may contribute to the reduced synthesis of C/EBP.
One consequence of the acute phase-induced alteration in the abundance of C/EBP-like proteins is to change the ratio of C/EBP and LAP in the nucleus and as a consequence the composition ofthe complex that forms at the C/EBP-binding site of various promoters. C/EBP and LAP are very similar in the primary amino acid sequence of their carboxy-terminal DNAbinding and dimerization domains. The two proteins heterodimerize readily and bind the same DNA sequences (20) (21) (22) (23) Fig. 1 b) and the activity of the transfected C/EBP-binding site-containing reporter plasmid (which is increased shortly after cytokine treatment, Fig. 2 d) are not known. However, adipocyte differentiation-dependent induction ofangiotensinogen mRNA is dependent on the activity of promoter elements other than the C/EBP-binding APRE (McGhee, R. E., Jr., et al., unpublished data). It follows therefore that cytokine treatment of 3T3-LI adipocytes may affect angiotensinogen gene expression by developmental mechanisms unrelated to changes in levels of C/EBP-like proteins.
One appealing hypothesis is that replacement of C/EBP by LAP during the acute phase may also account for some of the decrease in transcriptional activity of genes, such as the albumin gene that is negatively regulated by inflammatory cytokines (39, 40) . This hypothesis assigns a role to the cytokine-induced changes in the C/EBP-LAP ratio in determining the expression of those genes whose products are important in defining the metabolic profile of tissues such as adipose and liver (see 17) . Treatment of animals with cytokines, shown by us to affect the C/EBP-LAP ratio, is associated with marked changes in the metabolism of fat, carbohydrate, and protein culminating in the induction ofa syndrome ofcachexia (8, 40) . One would have to explain how the acute phase-induced change in the C/EBP-LAP ratio negatively affects the expression of some genes (e.g., albumin, 40) and positively affects the expression of others (e.g., haptoglobin, 22). Promoter-specific interactions with other transcription factors may provide part ofthe explanation. For example, the organization and function ofthe angiotensinogen gene is such that variations in the ability of the C/EBP-like complex that binds the APRE to interact with the adjacently bound glucocorticoid receptor, would be predicted to have a marked effect on promoter activity (25, 27) .
The physiological significance ofthe cytokine-induced alterations in C/EBP-like proteins that occur with cytokine treatment may not be restricted to a direct effect on promoter activity. One possibility suggested by our observations on differentiating 3T3-LI cells is that LAP may be an important C/EBP-like transcription activating protein in dividing cells, whereas C/EBP may serve the same function in terminally differentiated cells. In differentiating 3T3-L I cells, LAP levels are maximal at a time when the cells are undergoing the last two rounds of replication, before attaining the quiescent phase (41) . It is upon quiescence that C/EBP levels rise and LAP diminishes. It has been reported that a ligand-dependent conditional mutant of C/EBP is capable of inhibiting the replication of DNA in proliferating 3T3-L1 cells (19) . The paucity of C/EBP immunoreactivity in continuously dividing cells (42) is also consistent with an incompatibility between expression of C/ EBP and cellular division. These observations suggest that the purpose for the cytokine induced change in the levels ofC/EBP and LAP may be to provide C/EBP-like activating proteins in conditions in which a nonproliferating differentiated cell is preparing itself for the possibility of renewed replication. This occurrence may represent either an adaptive response to the tissue injury, commonly encountered during those perturbations that give rise to the secretion of TNF and IL-1, or as an evolutionary atavism, a vestige of times in which differentiated tissues retained a greater capacity for reparative proliferation. The observation that C/EBP levels fall during the liver regeneration that follows carbon tetrachloride poisoning is consistent with this notion (43) . Understanding the significance of the cytokine-induced change in C/EBP-like proteins will await further characterization ofthe complex that assembles on C/EBPbinding sites in promoters of relevant genes as well as a definition of the role of other proteins that interact with C/EBP.
